Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial

Obstetrics and Gynecology

Volumn 118, Issue 4, 2011, Pages 895-904

  Sibeko, Sengeziwe ^a,b   Baxter, Cheryl ^a,b   Yende, Nonhlanhla ^a,b   Karim, Quarraisha Abdool ^a,b   Karim, Salim S Abdool ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; TENOFOVIR;

ADULT; ARTICLE; CONDOM; CONTRACEPTION; FEMALE; FETUS DISTRESS; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; NEWBORN DEATH; NORMAL HUMAN; PATIENT COUNSELING; PREGNANCY OUTCOME; PREGNANCY RATE; PREGNANCY TERMINATION; PREGNANCY TEST; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; SPONTANEOUS ABORTION; TERM BIRTH;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY RATE; PROGESTINS; SOUTH AFRICA; YOUNG ADULT;

EID: 80053374676     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31822be512     Document Type: Article

References (21)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2010. Available at: www.unaids.org/globalreport/. Geneva: Joint United Nations Programme on HIV/AIDS; 2010. Retrieved February 11, 2011.
2. UNAIDS. 2008 report on the global AIDS epidemic update. Availableat:www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008-Global-report.asp. Geneva: Joint United Nations Programme on HIV/AIDS; 2008. Retrieved October 31, 2008.
3. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010;24:621-35.
4. AVAC. Ongoing and planned PreExposure Prophylaxis (PrEP) trials (February 2011). Available at: www.avac.org/ht/a/GetDocumentAction/i/3113. Retrieved February 2011.
5. Raymond EG, Taylor D, Cates W Jr, Tolley EE, Borasky D, Cancel A, et al. Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis 2007;34:1035-9. (Pubitemid 350158859)
6. Lagakos SW, Gable AR, eds. Methodological challenges in biomedical HIV prevention trials. Washington, DC: National Academy of Sciences; 2008.
7. Smart T. Microbicides 2006: high rates of pregnancy pose challenges for microbicide trials. Available at: www.aidsmap. com/en/news/3F76DCE3-83FA-4523- A920-5CB0829DD33A. asp. Retrieved June 2006.
8. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72.
9. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, doubleblind, randomized, placebo-controlled trial in Ghana. PLoS One 2007;2:e1312.
10. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474.
11. Puoti M, Brown RS Jr, Goodwin D, Zhang S, Fagan E. Tenofovir disoproxil fumarate in pregnancy: findings from the antiretroviral pregnancy registry. Dig Liver Dis 2009;41:A39-40.
12. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74.
13. Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 2011;12:67.
14. McCullagh P, Nelder JA. Generalized linear models. London (UK): Chapman and Hall, Inc; 1983.
15. Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M, et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 2010 Nov 3 [epub ahead of print].
16. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372: 1977-87.
17. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 2010;53:606-13.
18. Fraser IS, Jansen RP. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. Contraception 1983;27: 531-51. (Pubitemid 13045205)
19. Trussell J. Contraceptive failure in the United States. Contraception 2004;70:89-96. (Pubitemid 38993483)
20. Van Rompay KKA, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy throughout adulthood and pregnancy: summary of pharmacokinetics, biological and virological effects. Antimicrob Agents Chemother 2008;52:3144-60.
21. Schreiber CA, Sammel M, Hillier SL, Barnhart KT. A little bit pregnant: modeling how the accurate detection of pregnancy can improve HIV prevention trials. Am J Epidemiol 2009;169: 515-21.